Partner-assisted Skin Exams Benefit Some More Than Others

Share this content:
Training of patients with melanoma and partners in early detection skin self-examinations benefited those patients with low relationship quality.
Training of patients with melanoma and partners in early detection skin self-examinations benefited those patients with low relationship quality.

The training of patients with melanoma and their partners in early detection skin self-examinations (SSE) benefited those patients and their partners with low relationship quality more than others, a new study published online ahead of print in JAMA Dermatology has shown.1

Because training patients with early stage melanoma who are at risk for developing new melanomas to perform SSE may improve survival, researchers at The Pennsylvania State University in State College, PA, sought to determine for whom an educational intervention benefits most in a sample of patients with melanoma and their skin-check partners.

For the study, researchers enrolled 494 patients with stage 0 to 2B melanoma and their skin-check partners in ambulatory care dermatologic offices. Dyads of patients and their partners were randomly assigned to receive the training intervention or customary care. Follow-up assessments were performed at 12 months.

Results showed that everyone receiving the intervention experienced some benefit; however, those with below-average relationship quality and happiness experienced the greatest improvements in SSE self-efficacy.

Researchers found that patient-partner agreeability and partner motivation did not significantly impact the effects of the intervention on patients' SSE self-efficacy.

According to the American Cancer Society, about 73,870 new melanomas will be diagnosed in the United States in 2015 and about 9,940 people are expected to die from the disease.

Reference

  1. Hultgren BA, Turrisi R, Mallett KA, et al. Influence of quality of relationship between patient with melanoma and partner on partner-assisted skin examination education [published online ahead of print September 30, 2015]. JAMA Dermatol. doi: 10.1001/jamadermatol.2015.2819.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs